Back to Search Start Over

Long-Term Follow-Up of Percutaneous Coronary Intervention With Paclitaxel-Eluting Balloon Catheter.

Authors :
Sanchez-Perez, Ignacio
Abellan-Huerta, Jose
Jurado-Roman, Alfonso
Lopez-Lluva, Maria T.
Pinilla-Echeverri, Natalia
Perez-Diaz, Pedro
Piqueras-Flores, Jesus
Lozano-Ruiz-Poveda, Fernando
Source :
Angiology. Apr2021, Vol. 72 Issue 4, p364-370. 7p.
Publication Year :
2021

Abstract

Drug-eluting balloons currently constitute a therapeutic tool used in percutaneous coronary interventions (PCI). Long-term results remain unknown. We evaluated the prognosis of PCI using a second generation paclitaxel-eluting balloon (PEB) in real-world patients. We included all PCI with PEB in de novo or in-stent restenosis coronary lesions performed in our unit from March 2009 to March 2019. We assessed the composite of major adverse cardiovascular events (MACE) rate after a median follow-up of 42 months. Consecutive patients (n = 320) with 386 lesions were included; 46.9% presented with stable angina and 53.1% acute coronary syndromes; 52.6% of the lesions were in-stent restenosis and 47.3% de novo lesions with a mean diameter of 2.4 ± 0.5 mm. A bare metal stent was implanted in 6.7% and a drug-eluting stent in 8.5% of patients. The MACE rate was 8%: 10 (2.6%) cardiovascular deaths, 13 (3.4%) myocardial infarctions, and 16 (4.1%) target lesion revascularization. The all-cause death rate was 5.2%. No cases of thrombosis were recorded. In conclusion, PEB was a safe and effective tool to treat in-stent restenosis and de novo coronary lesions, especially small vessel disease, during long-term follow-up. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00033197
Volume :
72
Issue :
4
Database :
Academic Search Index
Journal :
Angiology
Publication Type :
Academic Journal
Accession number :
148852670
Full Text :
https://doi.org/10.1177/0003319720979246